Factor VIII Antibodies Demonstrate Type I or Type II Kinetics in Acquired Haemophilia A
Haemophilia · 2025
DOI: 10.1111/hae.15144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2025. Verfasst von Kirollos Kamel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Katharine Dormandy Haemophilia and Thrombosis Unit, Royal Free Hospital, London, UK. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Autoantibodies. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Acquired haemophilia A (AHA) is an acquired bleeding disorder resulting from autoantibodies against Factor VIII (FVIII). Previous studies have reported differences in FVIII inhibitor kinetics (type I or type II) in AHA compared to severe haemophilia A.
Aim
To characterise inhibitor kinetics in AHA and evaluate the proportions displaying type I, II or indeterminate kinetics.
Methods
Single‐centre retrospective study of inhibitor kinetics in adults with AHA. Type I kinetics were defined as linear FVIII inhibition with ≥ 97% FVIII inactivation. Type II kinetics were defined as non‐linear kinetics and inability to completely neutralise FVIII. Inhibitor titres were calculated using two methods outlined by the International Council for Standardisation in Haematology.
Results
Baseline samples from 34 patients were included. Fifteen samples (44.1%) exhibited type I kinetics, 16 samples (47.1%) exhibited type II kinetics and 3 (8.8%) were indeterminate. Plateau mean residual FVIII:C was higher for inhibitors displaying type II compared to type I kinetics (18.6 vs. 2.9 IU/dL, p < 0.0001). Non‐linear regression using a dose‐response curve without categorisation for kinetics type yielded a poor fit ( R 2 = 38%), which improved with refitting using categories of type I or II kinetics that explained 87% and 85% of the variability. The median difference in inhibitor titre between the two reporting methods was 5% and 15% in the type I and II kinetics groups, respectively.
Conclusion
FVIII autoantibodies demonstrate either type I or type II kinetics. Greater discrepancy in reported inhibitor titres depending on the method used is seen for inhibitors with type II kinetics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Katharine Dormandy Haemophilia and Thrombosis Unit, Royal Free Hospital, London, UK.
- Department of Haematology, Cancer Institute, University College London, London, UK.
ORCID-Profile: Kirollos Kamel, Anne Riddell, Pratima Chowdary, Paul Batty
Zitieren
APA
Kamel, K., Sardo Infirri, S., Riddell, A., Chowdary, P., & Batty, P. (2025). Factor VIII Antibodies Demonstrate Type I or Type II Kinetics in Acquired Haemophilia A. Haemophilia. https://doi.org/10.1111/hae.15144
Vancouver
Kamel K, Sardo Infirri S, Riddell A, Chowdary P, Batty P. Factor VIII Antibodies Demonstrate Type I or Type II Kinetics in Acquired Haemophilia A. Haemophilia. 2025. doi:10.1111/hae.15144
BibTeX
@article{Kamel2025,
author = {Kamel, Kirollos and Sardo Infirri, Sofia and Riddell, Anne and Chowdary, Pratima and Batty, Paul},
title = {Factor VIII Antibodies Demonstrate Type I or Type II Kinetics in Acquired Haemophilia A},
journal = {Haemophilia},
year = {2025},
doi = {10.1111/hae.15144}
}
EUVIMED